Management of posttransplant hepatitis C infection

Current Opinion in Organ Transplantation

Volumn 15, Issue 3, 2010, Pages 301-309

  Aytaman, Ayse ^a   Kaufman, Marina ^b   Terrault, Norah A ^c  

^a VA New York Harbor HCS   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Hepatitis C; Liver transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PREDNISONE; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DONOR SELECTION; DRUG POTENTIATION; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; RECURRENT DISEASE; REINFECTION; REVIEW; SURVIVAL RATE; VIRUS DETECTION;

ANTIVIRAL AGENTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77953286317     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283398237     Document Type: Review

References (110)

1. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137:1680-1686.
2. Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14:6467-6472.
3. Melero J, Berenguer M. Antiviral therapy in patients with HCV-cirrhosis. Ann Hepatol 2009; 8:292-297.
4. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27:1081-1085.
5. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255-262.
6. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206-212.
7. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396.
8. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9:905-915.
9. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
10. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830-836.
11. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15:1063-1071.
12. Bownik H, Saab S. The effects of hepatitis C recurrence on healthrelated quality of life in liver transplant recipients. Liver Int 2010; 30: 19-30.
13. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15:738-746.
14. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88:1214-1221.
15. Cescon M, Grazi GL, Cucchetti A, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15:782-789.
16. Pine JK, Aldouri A, Young AL, et al. Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl 2009; 15:1072-1082.
17. Yagci G, Fernandez LA, Knechtle SJ, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc 2008; 40:219-223.
18. Briceno J, Ciria R, Pleguezuelo M, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15:37-48.
19. Burra P, Loreno M, Russo FP, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009; 15:619-628.
20. Reese PP, Sonawane SB, Thomasson A, et al. Donor age and cold ischemia interact to produce inferior 90-day liver allograft survival. Transplantation 2008; 85:1737-1744.
21. Cassuto JR, Patel SA, Tsoulfas G, et al. The cumulative effects of cold ischemic time and older donor age on liver graft survival. J Surg Res 2008; 148:38-44.
22. Segev DL, Kucirka LM, Nguyen GC, et al. Effect modification in liver allografts with prolonged cold ischemic time. Am J Transplant 2008; 8:658-666.
23. Kuo A, Terrault NA. Is recurrent hepatitis C worse with living donors? Curr Opin Organ Transplant 2009; 14:240-244.
24. Coelho JC, Okawa L, Parolin MB, et al. Hepatitis C recurrence after living donor and cadaveric liver transplantation. Arq Gastroenterol 2009; 46:38-42.
25. Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of postliver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15:1872-1881.
26. Veldt BJ, Poterucha JJ, Watt KD, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9:1406-1413.
27. Sabharwal S, Delgado-Borrego A, Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl 2008; 14 (Suppl 2):S51-S57.
28. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417.
29. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
30. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 (Suppl 1):89-96.
31. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-830.
32. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
33. Waki K. UNOS Liver Registry: ten year survivals. Clin Transpl 2006; 29-39.
34. Neff GW, Kemmer N, Kaiser T, et al. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007; 39:3204-3206.
35. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004; 6:66-70.
36. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-2271.
37. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-1708. (Pubitemid 38702672)
38. Wittnich C, Belanger MP, Askin N, et al. Lower liver transplant success in females: gender differences in metabolic response to global ischemia. Transplant Proc 2004; 36:1485-1488.
39. Lai JC, Verna EC, Brown RS, et al. Hepatitis C virus (HCV) infected females are at higher risk of graft loss after liver transplantation (LT): a multicenter cohort study. AASLD; October 2009; Boston, MA: Hepatology; 2009. pp. 304A-305A.
40. Soric S, Belanger MP, Askin N, Wittnich C. Impact of female sex hormones on liver tissue lactic acidosis during ischemia. Transplantation 2007; 84:763-770.
41. Burkhardt M, Slotta JE, Garcia P, et al. The effect of estrogen on hepatic microcirculation after ischemia/reperfusion. Int J Colorectal Dis 2008; 23:113-119.
42. Segev DL, Thompson RE, Locke JE, et al. Prolonged waiting times for liver transplantation in obese patients. Ann Surg 2008; 248:863-870.
43. Gurusamy KS, Tsochatzis E, Xirouchakis E, et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010:CD006803.
44. Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation 2008; 86:418-422.
45. Lodato F, Berardi S, Gramenzi A, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28:450-457.
46. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746-1756.
47. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47:1371-1383.
48. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59:473-485.
49. Mudawi H, Helmy A, Kamel Y, et al. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: natural history and predictors of outcome. Ann Saudi Med 2009; 29:91-97.
50. Nguyen JH, Bonatti H, Dickson RC, et al. Long-term outcomes of donation after cardiac death liver allografts from a single center. Clin Transplant 2009; 23:168-173.
51. Llado L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44:710-716.
52. Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14:1752-1760.
53. Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(p) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521-1531.
54. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22:892-905.
55. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14:512-525.
56. Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009; 15:S1-S34.
57. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21-29.
58. Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12:1464-1472.
59. McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578-1585.
60. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006; 82:579-580. (Pubitemid 44290269)
61. Castells L NM, Berenguer M, Inmaculada F, et al. Cyclosporine-based immunosuppression is associated with lower relapse rate after end-of-treatment response to pegylated interferon plus ribavirin therapy in recurrent hepatitis C: a retrospective study. AASLD; October 2009; Boston, MA: Hepatology; 2009. pp. 316A-317A.
62. Orlando G, Manzia T, Baiocchi L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20 (1-2):43-47. Prospective study with 78-week follow-up of IMS sessation implications on posttransplant HCV.
63. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
64. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125-1130.
65. Nudo CG, Cortes RA, Weppler D, et al. Effect of pretransplant hepatitis C virus RNA status on posttransplant outcome. Transplant Proc 2008; 40:1449-1455.
66. Perrella A, Arenga G, Pisaniello D, et al. Elevated CD4p/CD25p T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc 2009; 41:1761-1766.
67. Borgogna C, Toniutto P, Smirne C, et al. Expression of the interferoninducible proteins MxA and IFI16 in liver allografts. Histopathology 2009; 54:837-846.
68. Tretheway D, Jain A, LaPoint R, et al. Should trichrome stain be used on all postliver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score? Liver Transpl 2008; 14:695-700.
69. PessoaMG, Alves VA, Wakamatsu A, et al. Posttransplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. Liver Int 2008; 28:807-813.
70. Micheloud D, Salcedo M, Banares R, et al. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 2009; 11:183-188.
71. Song ZZ. Re: assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 2008; 86:749; author reply.
72. Corradi F, Piscaglia F, Flori S, et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009; 41:217-225.
73. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
74. Bolognesi M, Quaglio C, Bombonato G, et al. Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echocolor Doppler. Liver Transpl 2008; 14:616-624.
75. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8:2426-2433. Retrospective review of 215 posttansplant HCV patients revealing reduced graft survival with AVT.
76. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8:679-687.
77. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199:1-10.
78. Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients postliver transplantation: case-control study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15:1826-1833.
79. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9:S58-S62.
80. Massoumi H, Elsiesy H, Khaitova V, et al. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009; 88:729-735.
81. Zimmermann T, Bocher WO, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20:583-590.
82. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78:1308-1311. (Pubitemid 39507969)
83. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831-838.
84. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65:82-86.
85. Urbani L, Mazzoni A, Colombatto P, et al. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers. Transplantation 2008; 86:1666-1671.
86. Kuo A, Tan V, Lan B, et al. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008; 14:1491-1497.
87. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12:1067-1076.
88. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40:669-674.
89. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78:1303-1307.
90. Oton E, Barcena R, Moreno-Planas JM, et al. HepatitisCrecurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6:2348-2355.
91. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13:1100-1108.
92. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peginterferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46:1009-1017.
93. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43:53-59.
94. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12:1805-1812.
95. Mukherjee S, Lyden E. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an openlabel series. Hepatogastroenterology 2006; 53:561-565. (Pubitemid 44386959)
96. Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006; 26:529-535.
97. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82:43-47.
98. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77:190-194.
99. Hirano K, Ichikawa T, Nakao K, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14:292-298.
100. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6:1586-1599.
101. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49:274-287.
102. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14:1766-1777.
103. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46:371-379.
104. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
105. Kwo PY LE, McCone J, Schiff ER, et al. Response-guided therapy (RGT) for boceprevir (BOC) combination treatment; results from HCV SPRINT-1. AASLD; October 2009; Boston, MA: Hepatology; 2009. p. 1035A.
106. Everson GT DG, Ferenci P, Alves K, et al. Telaprevir, Peginterferon alfa-2a and ribavirin improved rates of sustained virologic response (SVR) in 'difficult-to-cure' patients with chronic hepatitis C (CHC): a pooled analysis from the PROVE1 and PROVE2 trials. AASLD; October 2009; Boston, MA: Hepatology; 2009. p. 1025A.
107. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48:407-417.
108. Muir A SM, Zaman A, Yoffe B, et al. A phase 1B dose ranging study of 4 weeks of peg-interferon (IFN) lambda (PEG-RIL-29) in combination with ribavirin (RBV) in patients with chronic genotype 1 hepatitis C virus (HCV) infection. AASLD; October 2009; Boston, MA: Hepatology; 2009. pp. 1039A-1040A.
109. Novozhenov V ZN, Vinogradova E, Nikitin I, et al. Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype 1 infection. EASL; April 2007; Barcelona, Spain: Journal of Hepatology; 2007. p. s8.
110. Poordad F LE, Hassanein T, Shiffman ML, et al. Sustained virologic response (SVR) results for weight based taribavirin versus weight based ribavirin, in naive chronic hepatitis C, genotype 1 patients. AASLD; October 2009; Boston, MA: Hepatology; 2009. p. 334A.